USANA Health Sciences (USNA) Misses Q1 EPS by 3c; Lifts Guidance

USANA Health Sciences (NYSE: USNA) reported Q1 EPS of $1.45, $0.03 worse than the analyst estimate of $1.48. Revenue for the quarter came in at $308 million versus the consensus estimate of $301.47 million.

“We had an excellent start to the year largely due to continued strong consumer demand for our high-quality products,” said Kevin Guest, Chief Executive Officer and Chairman of the Board. “Our strong top-line performance was driven by double-digit year-over-year sales growth in each of our regions, and we expect the execution of our 2021 global growth strategy will continue to generate growth in the remainder of the year.”

GUIDANCE:

USANA Health Sciences sees FY2021 EPS of $6.15-$6.50, versus the consensus of $6.28. USANA Health Sciences sees FY2021 revenue of $1.24-1.28 billion, versus the consensus of $1.24 billion.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.

You May Also Be Interested In

• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• SunPower (SPWR) determined prior financial statements should no longer be relied upon
• NVR, Inc. (NVR) Tops Q1 EPS by 1244c